A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Inclusion Criteria: * Has given written informed consent before any study-related activity is performed * Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon® is intended to be used for treatment * Age greater than or equal to 18 years and less than 80 years * Advanced hormone-dependent prostate cancer without any other clinically significant disorder * Easten Cooperative Oncology Group score ≤ 2 * PSA ≥ 2 ng/mL at screening * Life expectancy of at least 12 months as per the investigator's judgement Exclusion Criteria: * Previous or concurrent hormonal management of prostate cancer * Contraindication for prescription of Firmagon® * Concurrent treatment with a 5-α-reductase inhibitor * Considered as a candidate for curative therapy * History of severe untreated asthma, anaphylactic reactions or severe urticaria and/or angioedema * QTc interval over 450 msec or risk factors for torsades de pointes or on Class IA and Class III anti arrhythmic medications * Cancer within the last 5 years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin * Known or suspected hepatic, symptomatic biliary disease (this includes moderate to severe chronic hepatic impairment) * Patients with clinically significant laboratory abnormalities / disorders other than prostate cancer * Patient with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections